Michal Juraska, PhD, MS

Dr. Juraska is a biostatistician engaged in statistical and clinical trial methods research meeting tangible needs in vaccine science (HIV, COVID-19, malaria, dengue, and other diseases). As a faculty member of the HIV Vaccine Trials Network (HVTN) and the COVID-19 Prevention Network (CoVPN), he has served as a lead statistician on several vaccine and monoclonal antibody efficacy trials and has led independent reporting to or served as a member of data monitoring committees. Dr. Juraska has expanded the fields of sieve analysis of breakthrough pathogen features and statistical evaluation of immune biomarkers as correlates of vaccine protection. He has contributed to developing clinical immunobridging strategies aimed at paving pathways to licensure based on immunological surrogate endpoints, in the absence of clinical outcomes.

Current Projects

Sieve and immune correlates analyses in HIV, COVID-19 and malaria vaccine trials

Prediction of HIV sensitivity to and prevention efficacy of broadly neutralizing antibodies based on HIV sequence and structural knowledge

Statistical methods and software for surrogate endpoint-based vaccine approval

Statistical design of HIV vaccine and monoclonal antibody efficacy trials in current prevention landscape

Bibliography
 

Software

Code repositories